Pathstone Holdings
NRSN icon

Pathstone Holdings’s NeuroSense Therapeutics NRSN Stock Holding History

Pathstone Holdings’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9K Hold
16,528
– – ﹤0.01% 2331
2026
Q1 		$12.5K Hold
16,528
– – ﹤0.01% 2213
2025
Q4 		$12.7K Buy
+16,528
New +$17.4K ﹤0.01% 2215

Other funds holding NRSN

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Pathstone Holdings's NRSN Position: Q2 2026 in Review

Pathstone Holdings held its NeuroSense Therapeutics (NRSN) position steady in Q2 2026 at 16,528 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2331.

Pathstone Holdings first reported a position in NRSN in Q4 2025 and has held it in 3 quarters since. The position peaked at $12.7K in Q4 2025. 12 funds tracked by Wall St. Rank hold NRSN as of Q2 2026.

  • Pathstone Holdings held 16,528 shares of NeuroSense Therapeutics worth $11.9K as of Q2 2026.
  • Pathstone Holdings left its NeuroSense Therapeutics share count unchanged in Q2 2026.
  • NeuroSense Therapeutics made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #2331 holding.
  • Pathstone Holdings first reported a position in NeuroSense Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Pathstone Holdings's NeuroSense Therapeutics position peaked at $12.7K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.